Robust, GMP-compliant quantitative assay procedures are critical for quality control in pharmaceutical manufacturing. This whitepaper explores the advantages of using quantitative Nuclear Magnetic Resonance (qNMR) with the Fourier 80 benchtop spectrometer for analyzing fluorinated active pharmaceutical ingredients.
Thanks to its multinuclear capabilities, the Fourier 80 supports straightforward implementation of 19F NMR quantitative assays—fully aligned with regulatory expectations.
The high specificity of 19F NMR simplifies procedure development and enables reliable quantification even in complex formulations, such as finished drug products. This approach streamlines both design and execution, making it a practical solution for modern QC environments.
Download the full whitepaper here.
About Bruker BioSpin - NMR, EPR and Imaging - Pharma
Welcome to Bruker BioSpin and the world's most comprehensive range of NMR and EPR spectroscopy and preclinical imaging research tools. The Bruker BioSpin Group of companies develop, manufacture and supply technology to research establishments, commercial enterprises and multi-national corporations across countless industries and fields of expertise.
Bruker BioSpin is continuing to revolutionize the design, manufacture and distribution of life science, preclinical, process control and analytical research tools based on magnetic resonance and multimodal imaging technologies. Bruker BioSpin is the worldwide technology and market leader in magnetic resonance technologies (NMR, EPR) and offers the largest portfolio of imaging modalities for preclinical and industrial research under a single brand.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.